Rhonda Hettinger, NP
Nurse Practitioner · Clarksville, INNPI 1407844996
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,240 of the $37,578 with a category attached, or 67.2%. AstraZeneca accounts for 63.4% of it on its own, with 46 other manufacturers making up the rest. Reporting peaked in 2021 at $14,210 and has fallen 82.4% since, to $2,498 in 2025. Among nurse practitioner clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 784 payments — averaging $47.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$24K
- Esperion Therapeutics, Inc.$4K
- AbbVie$984
- Takeda Pharmaceuticals U.S.A., Inc.$894
- Novo Nordisk$763
- Regeneron Healthcare Solutions, Inc.$631
- plus $6K from 41 others
What the payments were for
- Speaking & faculty fees$25,24067%
- Travel & lodging$140%
- Food & beverage$12,23633%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,578 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $142,721 |
| EliquisApixaban | 154 | $136,914 |
| XareltoRivaroxaban | 57 | $73,470 |
| TrulicityDulaglutide | 62 | $67,242 |
| FarxigaDapagliflozin Propanediol | 66 | $63,204 |
| Xigduo XrDapaglifloz Propaned/Metformin | 58 | $51,359 |
| MounjaroTirzepatide | 32 | $34,467 |
| Repatha SureclickEvolocumab | 21 | $32,595 |
| Praluent PenAlirocumab | 21 | $31,267 |
| MyrbetriqMirabegron | 42 | $27,748 |
| JanuviaSitagliptin Phosphate | 30 | $27,158 |
| LinzessLinaclotide | 36 | $27,114 |
| VascepaIcosapent Ethyl | 56 | $24,731 |
| Ranolazine ErRanolazine | 115 | $21,772 |
| SynthroidLevothyroxine Sodium | 308 | $20,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $763 | $142,721107 claims |
| PfizerEliquis | $367 | $136,914154 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $373 | $101,71094 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $23,841 | $87,321103 claims |
| Johnson & JohnsonXarelto | $344 | $73,47057 claims |
| AbbVieLinzess, Synthroid | $984 | $47,285344 claims |
| Boehringer IngelheimSynjardy Xr, Tradjenta, Jardiance | $146 | $43,75643 claims |
| Astellas Pharma US IncMyrbetriq | $67 | $27,74842 claims |
| MerckJanuvia | $371 | $27,15830 claims |
| NovartisEntresto | $612 | $20,01314 claims |
| Esperion Therapeutics, Inc.Nexlizet | $4,387 | $10,72111 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $212 | $3,689412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Clarksville
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
- Jennifer MaahsIndianapolis$36K
- Amber MillerLawrenceburg$32K
- Dawn SteppIndianapolis$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.